Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertensive patients

Roberto Fogari, Annalisa Zoppi, Luca Corradi, Pierangelo Lazzari, Amedeo Mugellini, Paola Lusardi

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

Aims. The aim of this study was to compare the effects of the ACE-inhibitor lisinopril and the angiotensin II receptor antagonist losartan on insulin sensitivity in the treatment of non diabetic hypertensives. Methods. Twenty-five non diabetic subjects with mild to moderate hypertension, 11 females and 14 males, aged 44-63 years, after a 4-week wash-out period on placebo, were randomized to receive lisinopril 20 mg once daily or losartan 50 mg once daily for 6 weeks. Following another 4-week wash-out period, patients were crossed to the alternative regimen for further 6 weeks. At the end of the placebo and of the active treatment periods, blood pressure (BP) was measured (by standard mercury sphygmomanometer, Korotkoff I and V) and insulin sensitivity was assessed by the euglycaemic hyperinsulinaemic clamp technique. Glucose infusion rate (GIR) during the last 30 min of clamp and total glucose requirement (TGR) were evaluated. Results. Both lisinopril and losartan significantly reduced SBP (by a mean of 20.2 and 17.2 mmHg, respectively) and DBP (by a mean of 15.2 and 12.3 mmHg, respectively), with no difference between the two treatments. GIR, used as an indicator of insulin sensitivity, was significantly increased by lisinopril (+1.5 mg mi-1 kg-1, P <0.05 vs baseline) but not by losartan (+0.42 mg min-1 kig-1, NS), the difference between the two drugs being statistically significant (P <0.05). TGR was increased by lisinopril (+7.3 g, P <0.05 vs baseline), whereas losartan did not significantly modify it (+1.9 g, NS). Conclusions. In conclusion, with all cautions due to an absence in this study of a randomized placebo phase, our findings suggest that lisinopril improved insulin sensitivity whereas losartan did not affect it.

Original languageEnglish
Pages (from-to)467-471
Number of pages5
JournalBritish Journal of Clinical Pharmacology
Volume46
Issue number5
DOIs
Publication statusPublished - 1998

Fingerprint

Lisinopril
Losartan
Insulin Resistance
Glucose Clamp Technique
Placebos
Glucose
Therapeutics
Sphygmomanometers
Angiotensin Receptor Antagonists
Mercury
Angiotensin-Converting Enzyme Inhibitors
Blood Pressure
Hypertension
Pharmaceutical Preparations

Keywords

  • Hypertension treatment
  • Insulin sensitivity
  • Lisinopril
  • Losartan

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertensive patients. / Fogari, Roberto; Zoppi, Annalisa; Corradi, Luca; Lazzari, Pierangelo; Mugellini, Amedeo; Lusardi, Paola.

In: British Journal of Clinical Pharmacology, Vol. 46, No. 5, 1998, p. 467-471.

Research output: Contribution to journalArticle

Fogari, Roberto ; Zoppi, Annalisa ; Corradi, Luca ; Lazzari, Pierangelo ; Mugellini, Amedeo ; Lusardi, Paola. / Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertensive patients. In: British Journal of Clinical Pharmacology. 1998 ; Vol. 46, No. 5. pp. 467-471.
@article{373218d8838347a098a507aea43d4d56,
title = "Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertensive patients",
abstract = "Aims. The aim of this study was to compare the effects of the ACE-inhibitor lisinopril and the angiotensin II receptor antagonist losartan on insulin sensitivity in the treatment of non diabetic hypertensives. Methods. Twenty-five non diabetic subjects with mild to moderate hypertension, 11 females and 14 males, aged 44-63 years, after a 4-week wash-out period on placebo, were randomized to receive lisinopril 20 mg once daily or losartan 50 mg once daily for 6 weeks. Following another 4-week wash-out period, patients were crossed to the alternative regimen for further 6 weeks. At the end of the placebo and of the active treatment periods, blood pressure (BP) was measured (by standard mercury sphygmomanometer, Korotkoff I and V) and insulin sensitivity was assessed by the euglycaemic hyperinsulinaemic clamp technique. Glucose infusion rate (GIR) during the last 30 min of clamp and total glucose requirement (TGR) were evaluated. Results. Both lisinopril and losartan significantly reduced SBP (by a mean of 20.2 and 17.2 mmHg, respectively) and DBP (by a mean of 15.2 and 12.3 mmHg, respectively), with no difference between the two treatments. GIR, used as an indicator of insulin sensitivity, was significantly increased by lisinopril (+1.5 mg mi-1 kg-1, P <0.05 vs baseline) but not by losartan (+0.42 mg min-1 kig-1, NS), the difference between the two drugs being statistically significant (P <0.05). TGR was increased by lisinopril (+7.3 g, P <0.05 vs baseline), whereas losartan did not significantly modify it (+1.9 g, NS). Conclusions. In conclusion, with all cautions due to an absence in this study of a randomized placebo phase, our findings suggest that lisinopril improved insulin sensitivity whereas losartan did not affect it.",
keywords = "Hypertension treatment, Insulin sensitivity, Lisinopril, Losartan",
author = "Roberto Fogari and Annalisa Zoppi and Luca Corradi and Pierangelo Lazzari and Amedeo Mugellini and Paola Lusardi",
year = "1998",
doi = "10.1046/j.1365-2125.1998.00811.x",
language = "English",
volume = "46",
pages = "467--471",
journal = "British Journal of Clinical Pharmacology",
issn = "0306-5251",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertensive patients

AU - Fogari, Roberto

AU - Zoppi, Annalisa

AU - Corradi, Luca

AU - Lazzari, Pierangelo

AU - Mugellini, Amedeo

AU - Lusardi, Paola

PY - 1998

Y1 - 1998

N2 - Aims. The aim of this study was to compare the effects of the ACE-inhibitor lisinopril and the angiotensin II receptor antagonist losartan on insulin sensitivity in the treatment of non diabetic hypertensives. Methods. Twenty-five non diabetic subjects with mild to moderate hypertension, 11 females and 14 males, aged 44-63 years, after a 4-week wash-out period on placebo, were randomized to receive lisinopril 20 mg once daily or losartan 50 mg once daily for 6 weeks. Following another 4-week wash-out period, patients were crossed to the alternative regimen for further 6 weeks. At the end of the placebo and of the active treatment periods, blood pressure (BP) was measured (by standard mercury sphygmomanometer, Korotkoff I and V) and insulin sensitivity was assessed by the euglycaemic hyperinsulinaemic clamp technique. Glucose infusion rate (GIR) during the last 30 min of clamp and total glucose requirement (TGR) were evaluated. Results. Both lisinopril and losartan significantly reduced SBP (by a mean of 20.2 and 17.2 mmHg, respectively) and DBP (by a mean of 15.2 and 12.3 mmHg, respectively), with no difference between the two treatments. GIR, used as an indicator of insulin sensitivity, was significantly increased by lisinopril (+1.5 mg mi-1 kg-1, P <0.05 vs baseline) but not by losartan (+0.42 mg min-1 kig-1, NS), the difference between the two drugs being statistically significant (P <0.05). TGR was increased by lisinopril (+7.3 g, P <0.05 vs baseline), whereas losartan did not significantly modify it (+1.9 g, NS). Conclusions. In conclusion, with all cautions due to an absence in this study of a randomized placebo phase, our findings suggest that lisinopril improved insulin sensitivity whereas losartan did not affect it.

AB - Aims. The aim of this study was to compare the effects of the ACE-inhibitor lisinopril and the angiotensin II receptor antagonist losartan on insulin sensitivity in the treatment of non diabetic hypertensives. Methods. Twenty-five non diabetic subjects with mild to moderate hypertension, 11 females and 14 males, aged 44-63 years, after a 4-week wash-out period on placebo, were randomized to receive lisinopril 20 mg once daily or losartan 50 mg once daily for 6 weeks. Following another 4-week wash-out period, patients were crossed to the alternative regimen for further 6 weeks. At the end of the placebo and of the active treatment periods, blood pressure (BP) was measured (by standard mercury sphygmomanometer, Korotkoff I and V) and insulin sensitivity was assessed by the euglycaemic hyperinsulinaemic clamp technique. Glucose infusion rate (GIR) during the last 30 min of clamp and total glucose requirement (TGR) were evaluated. Results. Both lisinopril and losartan significantly reduced SBP (by a mean of 20.2 and 17.2 mmHg, respectively) and DBP (by a mean of 15.2 and 12.3 mmHg, respectively), with no difference between the two treatments. GIR, used as an indicator of insulin sensitivity, was significantly increased by lisinopril (+1.5 mg mi-1 kg-1, P <0.05 vs baseline) but not by losartan (+0.42 mg min-1 kig-1, NS), the difference between the two drugs being statistically significant (P <0.05). TGR was increased by lisinopril (+7.3 g, P <0.05 vs baseline), whereas losartan did not significantly modify it (+1.9 g, NS). Conclusions. In conclusion, with all cautions due to an absence in this study of a randomized placebo phase, our findings suggest that lisinopril improved insulin sensitivity whereas losartan did not affect it.

KW - Hypertension treatment

KW - Insulin sensitivity

KW - Lisinopril

KW - Losartan

UR - http://www.scopus.com/inward/record.url?scp=0031763235&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031763235&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2125.1998.00811.x

DO - 10.1046/j.1365-2125.1998.00811.x

M3 - Article

VL - 46

SP - 467

EP - 471

JO - British Journal of Clinical Pharmacology

JF - British Journal of Clinical Pharmacology

SN - 0306-5251

IS - 5

ER -